Establishing and Validating an Aging-Related Prognostic Signature in Osteosarcoma.

IF 3.8 3区 医学 Q2 CELL & TISSUE ENGINEERING
Stem Cells International Pub Date : 2023-02-23 eCollection Date: 2023-01-01 DOI:10.1155/2023/6245160
Yibo Ma, Shuo Zheng, Mingjun Xu, Changjian Chen, Hongtao He
{"title":"Establishing and Validating an Aging-Related Prognostic Signature in Osteosarcoma.","authors":"Yibo Ma, Shuo Zheng, Mingjun Xu, Changjian Chen, Hongtao He","doi":"10.1155/2023/6245160","DOIUrl":null,"url":null,"abstract":"<p><p>Aging is an inevitable process that biological changes accumulate with time and results in increased susceptibility to different tumors. But currently, aging-related genes (ARGs) in osteosarcoma were not clear. We investigated the potential prognostic role of ARGs and established an ARG-based prognostic signature for osteosarcoma. The transcriptome data and corresponding clinicopathological information of patients with osteosarcoma were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Molecular subtypes were generated based on prognosis-related ARGs obtained from univariate Cox analysis. With ARGs, a risk signature was built by univariate, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analyses. Differences in clinicopathological features, immune infiltration, immune checkpoints, responsiveness to immunotherapy and chemotherapy, and biological pathways were assessed according to molecular subtypes and the risk signature. Based on risk signature and clinicopathological variables, a nomogram was established and validated. Three molecular subtypes with distinct clinical outcomes were classified based on 36 prognostic ARGs for osteosarcoma. A nine-ARG-based signature in the TCGA cohort, including <i>BMP8A</i>, <i>CORT</i>, <i>SLC17A9</i>, <i>VEGFA</i>, <i>GAL</i>, <i>SSX1</i>, <i>RASGRP2</i>, <i>SDC3</i>, and <i>EVI2B</i>, has been created and developed and could well perform patient stratification into the high- and low-risk groups. There were significant differences in clinicopathological features, immune checkpoints and infiltration, responsiveness to immunotherapy and chemotherapy, cancer stem cell, and biological pathways among the molecular subtypes. The risk signature and metastatic status were identified as independent prognostic factors for osteosarcoma. A nomogram combining ARG-based risk signature and metastatic status was established, showing great prediction accuracy and clinical benefit for osteosarcoma OS. We characterized three ARG-based molecular subtypes with distinct characteristics and built an ARG-based risk signature for osteosarcoma prognosis, which could facilitate prognosis prediction and making personalized treatment in osteosarcoma.</p>","PeriodicalId":21962,"journal":{"name":"Stem Cells International","volume":"1 1","pages":"6245160"},"PeriodicalIF":3.8000,"publicationDate":"2023-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643040/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stem Cells International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/6245160","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0

Abstract

Aging is an inevitable process that biological changes accumulate with time and results in increased susceptibility to different tumors. But currently, aging-related genes (ARGs) in osteosarcoma were not clear. We investigated the potential prognostic role of ARGs and established an ARG-based prognostic signature for osteosarcoma. The transcriptome data and corresponding clinicopathological information of patients with osteosarcoma were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Molecular subtypes were generated based on prognosis-related ARGs obtained from univariate Cox analysis. With ARGs, a risk signature was built by univariate, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analyses. Differences in clinicopathological features, immune infiltration, immune checkpoints, responsiveness to immunotherapy and chemotherapy, and biological pathways were assessed according to molecular subtypes and the risk signature. Based on risk signature and clinicopathological variables, a nomogram was established and validated. Three molecular subtypes with distinct clinical outcomes were classified based on 36 prognostic ARGs for osteosarcoma. A nine-ARG-based signature in the TCGA cohort, including BMP8A, CORT, SLC17A9, VEGFA, GAL, SSX1, RASGRP2, SDC3, and EVI2B, has been created and developed and could well perform patient stratification into the high- and low-risk groups. There were significant differences in clinicopathological features, immune checkpoints and infiltration, responsiveness to immunotherapy and chemotherapy, cancer stem cell, and biological pathways among the molecular subtypes. The risk signature and metastatic status were identified as independent prognostic factors for osteosarcoma. A nomogram combining ARG-based risk signature and metastatic status was established, showing great prediction accuracy and clinical benefit for osteosarcoma OS. We characterized three ARG-based molecular subtypes with distinct characteristics and built an ARG-based risk signature for osteosarcoma prognosis, which could facilitate prognosis prediction and making personalized treatment in osteosarcoma.

骨肉瘤中衰老相关预后特征的建立和验证
衰老是一个不可避免的过程,生物变化会随着时间的推移而积累,并导致对不同肿瘤的易感性增加。但目前,骨肉瘤中的衰老相关基因(ARGs)尚不清楚。我们研究了ARGs的潜在预后作用,并建立了一个基于ARG的骨肉瘤预后标志。骨肉瘤患者的转录组数据和相应的临床病理信息来自癌症基因组图谱(TCGA)和基因表达综合(GEO)数据库。分子亚型是根据从单变量Cox分析中获得的预后相关ARG生成的。对于ARGs,通过单变量、最小绝对收缩和选择算子(LASSO)和多变量Cox回归分析建立风险特征。根据分子亚型和风险特征评估临床病理特征、免疫浸润、免疫检查点、对免疫疗法和化疗的反应性以及生物学途径的差异。基于风险特征和临床病理变量,建立并验证了列线图。根据骨肉瘤的36个预后ARGs,对具有不同临床结果的三种分子亚型进行了分类。TCGA队列中基于ARG的9个特征,包括BMP8A、CORT、SLC17A9、VEGFA、GAL、SSX1、RASGRP2、SDC3和EVI2B,已经创建和开发,可以很好地将患者分层为高风险组和低风险组。分子亚型在临床病理特征、免疫检查点和浸润、免疫疗法和化疗反应性、癌症干细胞和生物学途径方面存在显著差异。风险特征和转移状态被确定为骨肉瘤的独立预后因素。建立了一个结合基于ARG的风险特征和转移状态的列线图,显示了骨肉瘤OS的良好预测准确性和临床效益。我们对具有不同特征的三种基于ARG的分子亚型进行了表征,并构建了骨肉瘤预后的ARG风险标志,这有助于骨肉瘤的预后预测和个性化治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Stem Cells International
Stem Cells International CELL & TISSUE ENGINEERING-
CiteScore
8.10
自引率
2.30%
发文量
188
审稿时长
18 weeks
期刊介绍: Stem Cells International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies in all areas of stem cell biology and applications. The journal will consider basic, translational, and clinical research, including animal models and clinical trials. Topics covered include, but are not limited to: embryonic stem cells; induced pluripotent stem cells; tissue-specific stem cells; stem cell differentiation; genetics and epigenetics; cancer stem cells; stem cell technologies; ethical, legal, and social issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信